Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis

[1] Escobar MA(2003)Treatment on demand—in vivo dose finding studies Haemophilia 9 360-367

[2] Nilsson IM(1992)Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B J Int Med 232 25-32

[3] Berntorp E(2003)Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective Haemophilia 9 101-110

[4] Löfqvist T(2011)Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia Haemophilia 17 2-10

[5] Pettersson H(1997)The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications Haemophilia 3 1-8

[6] Björkman S(2001)Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia Clin Pharmacokinet 40 815-832

[7] Collins PW(2011)A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing Haemophilia 17 179-184

[8] Fischer K(1994)Pharmacokinetics of factor IX in patients with haemophilia B: methodological aspects and physiological interpretation Eur J Clin Pharmacol 46 325-332

[9] Morfini M(1969)Treatment of hemophilia B with a new clotting factor concentrate New Engl J Med 280 581-586

[10] Blanchette VS(1993)Biochemical and in vivo properties of high purity factor IX concentrates Thrombos Haemostas 70 768-73

[1] Escobar MA(2003)Treatment on demand—in vivo dose finding studies Haemophilia 9 360-367

[2] Nilsson IM(1992)Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B J Int Med 232 25-32

[3] Berntorp E(2003)Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective Haemophilia 9 101-110

[4] Löfqvist T(2011)Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia Haemophilia 17 2-10

[5] Pettersson H(1997)The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications Haemophilia 3 1-8

[6] Björkman S(2001)Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia Clin Pharmacokinet 40 815-832

[7] Collins PW(2011)A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing Haemophilia 17 179-184

[8] Fischer K(1994)Pharmacokinetics of factor IX in patients with haemophilia B: methodological aspects and physiological interpretation Eur J Clin Pharmacol 46 325-332

[9] Morfini M(1969)Treatment of hemophilia B with a new clotting factor concentrate New Engl J Med 280 581-586

[10] Blanchette VS(1993)Biochemical and in vivo properties of high purity factor IX concentrates Thrombos Haemostas 70 768-73